Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845454 · ClinicalTrials.gov registry record · NA
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A NA study, sponsored by CSA Medical.
- Terminated
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT01845454 is a NA study that was terminated before completion, run by CSA Medical. The registered enrollment target is 36 participants.
The verdict
NCT01845454, a NA study, was terminated before completion, sponsored by CSA Medical.
- TERMINATED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the percentage segment regression after spray cryotherapy in a dose-escalation study performed in patients with dysplastic Barrett's Esophagus (BE) using trūFreeze™ spray cryotherapy within the currently recommended therapeutic range. Secondary objectives are the determination of safety related outcomes such as esophageal stricture.
Interventions
- DEVICE trūFreeze™ Spray Cryotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01845454
The ClinicalTrials.gov registry entry for NCT01845454 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSA Medical, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which trūFreeze™ Spray Cryotherapy is the first listed.
NCT01845454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01845454 about?
NCT01845454 is a clinical study titled "A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy". The primary objective of this study is to determine the percentage segment regression after spray cryotherapy in a dose-escalation study performed in patients with dysplastic Barrett's Esophagus (BE) using trūFreeze™ spray cryotherapy within the currently recommended therapeutic range. Secondary ob...
What is the current status of trial NCT01845454?
This trial is currently terminated. It is a NA study. The enrollment target is 36 participants. The study started on 2013-04. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01845454?
The interventions under investigation include: trūFreeze™ Spray Cryotherapy (DEVICE).
Who is sponsoring clinical trial NCT01845454?
This trial is sponsored by CSA Medical, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.